Rafinlar 75mg Capsule

Treat malignant melanoma and other skin cancer

Most of the medicine cause side effects, patient experience symptoms while using Rafinlar 75mg capsule. Reach out to the doctor instantly if any of these symptoms persist:

• Fatigue or weakness
  
• Headache
  
• Fever
  
• Chills
  
• Dizziness or light headedness
  
• Loss of appetite
  
• Dry skin or rash
  
• Joint pain or muscle pain
  
• Cough or shortness of breath
  
• Chest pain or heart palpitations
  
• Bleeding or bruising easily
  

• Rafinlar 75mg capsule is a prescription based medicine that should be taken under the consultation of a healthcare provider.
• Most of the time it must be consumed with food to increase absorption and make the treatment more effective.
• The capsule is taken orally, in the form of capsule at the same time everyday.
• The correct dose and duration of the capsule depend on the patient medical history and response to the treatment.
• Do not self administer.

• Rafinlar capsule is targeted based hormonal therapy that is used in treatment of malignant melanoma and other skin cancer.
• It acts as an antineoplastic (anti-cancer) agent that works by blocking the activity of mutated BRAF proteins which are responsible for uncontrolled growth of cancer cells in the body.
• The medicine makes the treatment effective as it directly targets the tumor without damaging the healthy cells.

• Puszkiel, A., Noé, G., Bellesoeur, A., Kramkimel, N., Paludetto, M. N., Thomas-Schoemann, A., ... & Blanchet, B. (2019). Clinical pharmacokinetics and pharmacodynamics of dabrafenib. Clinical Pharmacokinetics, 58(4), 451-467.
  
• Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, H. T., Brown, M. P., ... & Kefford, R. F. (2014). Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). Clinical Cancer Research, 20(17), 4449-4458.
  
• Ballantyne, A. D., & Garnock-Jones, K. P. (2013). Dabrafenib: first global approval. Drugs, 73(12), 1367-1376.
  
• Denton, C. L., Minthorn, E., Carson, S. W., Young, G. C., Richards‐Peterson, L. E., Botbyl, J., ... & Ouellet, D. (2013). Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation‐positive solid tumors. The Journal of Clinical Pharmacology, 53(9), 955-961.
  
• Ouellet, D., Gibiansky, E., Leonowens, C., O'Hagan, A., Haney, P., Switzky, J., & Goodman, V. L. (2014). Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites. The Journal of Clinical Pharmacology, 54(6), 696-706.